ArticleACS nanoscience Au2026
Combating Antimicrobial Resistance with Hydrophilic and Eco-Friendly Membrane-Active Antibiotics Derived from Biological Nanoparticles.
Article in ACS nanoscience Au, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
The ever-increasing use of antibiotics and the accumulation of antibiotic waste in ecosystems are expediting antimicrobial resistance (AMR). Our next-generation antibiotics should aim for a different antimicrobial mechanism that is less conducive to AMR, a wider therapeutic window tolerant to drug titration, and a quicker deactivation strategy responsive to environmental stimuli. Membrane-active antimicrobials (MAAs) have the potential to thwart AMR, but the lipophilicity of current MAAs gives rise to their broad-spectrum cytotoxicity. Here, we show that biological nanoparticles, such as cyclodextrin and phytoglycogen, can be transformed into potent MAAs with low cytotoxicity by grafting them with hydrophilic polymer brushes. In service, these hydrophilic nanoantibiotics kill bacteria by inducing pore formation exclusively on microbial membranes rich in negative curvature lipids, a bactericidal mode less likely to incur AMR. After service, they are degraded and deactivated by biomass recycling enzymes that are abundant in ecosystems. This study illuminates a new paradigm to combat AMR with hydrophilic and eco-friendly membrane-active antibiotics derived from biological nanoparticles.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.